New study tracks how ILARIS works in everyday care for rare inflammatory diseases

NCT ID NCT07517250

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Apr 12, 2026 · Last updated May 22, 2026 · Updated 6 times

Summary

This study looks at how patients with Familial Mediterranean Fever (FMF) or Still's disease (including juvenile and adult forms) are treated with the drug canakinumab (ILARIS) in real-world clinics across Europe and Israel. Researchers will track 160 people who have been on the drug for at least 6 months to see how well it controls their disease and whether they can reduce other medications like steroids. The goal is to better understand long-term outcomes and treatment patterns outside of a controlled trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Locations

Novartis
RECRUITING

Basel, CH-4056, Switzerland

Conditions

Explore the condition pages connected to this study.

ADULT ONSET STILL DISEASE FAMILIAL MEDITERRANEAN FEVER STILL DISEASE STILL DISEASE SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS